Global Diabetes Therapeutics Market

Description

Market Overview

The Global Diabetes Therapeutics Market reached US$ 61.4 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 106.2 million by 2030. The Global Diabetes Therapeutics Market is expected to exhibit a CAGR of 7.2% during the forecast period 2023-2030.

Diabetes draws attention to a spreading disease that is causing a significant social and economic dilemma in nations worldwide. Despite scientific advancements, greater healthcare facilities, and increased literacy rates, the disease still affects many people, especially in middle- and low-income nations.

Market Dynamics

Increasing Diabetes Management is Boosting the Global Diabetes Therapeutics Market Growth During the Forecast Period

The increased research for alternative treatment options is driving the global market, such as Diabetes Research Institute in the US, which is developing a bioengineered mini-organ where insulin-producing cells are encapsulated within a protective barrier. This mini-pancreas is implanted into the omentin, a part of the abdominal lining.

In April 2023, Glooko, Inc. announced a new global cooperation with Hedia to include its technology in Glooko's platforms for diabetes management used by healthcare professionals and patients. By combining linked care, remote patient monitoring, and digital therapeutic technologies, the cooperation will offer an interoperable solution that will improve access for patients with Type 1 and Type 2 diabetes who need guidance on how much bolus insulin to administer.

Collaboration Among Key Players Provides the Global Diabetes Therapeutics Market Growth Opportunities

Technological advances that provide excellent opportunities for high-volume manufacturing and increased reach through online platforms have made the market competitive. Major market players are Novo Nordisk, AstraZeneca, Pfizer, Abbott India Ltd, Eli Lilly, AbbVie Inc., Dr. Reddy`s Labs, Sanofi, Novartis International, Merck, Boehringer Ingelheim and others.

For instance, in February 2022, To usher in a new era of comprehensive diabetes management care, Abbott, the world leader in healthcare, announced new partnerships with important health-tech partners BeatO and Sugar. fit, PharmEasy, GOQii, 1MG, Zyla Health, HealthifyMe, and Fitterfly.

Abbott hopes to reach 8 million people with diabetes through these partnerships, 6.5 million of whom can access these solutions through PharmEasy and 1MG. Along with remote consultations, coaching tailored specifically for people with diabetes, and meal planning, the business focuses on maintaining an effective glucose level.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant impact on the diabetes therapeutics market. Telemedicine services were rapidly expanded to preserve the continuity of care during the pandemic. Healthcare professionals could treat diabetes patients remotely, have virtual consultations, and prescribe medication thanks to telemedicine. The accessibility and availability of diabetic treatments have benefited from the rising use of telemedicine.

Russia-Ukraine Conflict Analysis

The impact of the Russia-Ukraine war on the diabetes therapeutics market is complex and multifaceted. The conflict may impact research and development operations in the affected regions. Disruptions to scientific institutions may hamper research and development activities aimed at developing diabetic therapies, decreased financing, or brain drain caused by the emigration of skilled researchers and medical personnel.

Segment Analysis

The Global Diabetes Therapeutics Market is segmented based on type, therapy type, end-user, and region.

The Injectable Antidiabetics Segment is Expected to Hold a Dominant Position in the Market Over the Forecast Period

The injectable antidiabetics segment accounted for the highest market stake accounting for approximately 34.7% of the diabetes therapeutics market in 2022. Injectable antidiabetics, commonly referred to as injectable diabetes treatments, are drugs that are given intravenously to people with diabetes in order to monitor and control their blood sugar levels. People with type 1 diabetes, type 2 diabetes that is not well controlled with oral drugs, or people who need insulin therapy often use these medications. Insulin is the primary injectable antidiabetic medication used to manage diabetes. It is a hormone that helps regulate blood sugar levels.

Geographical Analysis

Increasing Collaborations And Partnerships Among the Key Players and Advancement in Diabetes Therapeutics Dominate the North American Region

North America is expected to dominate the diabetes therapeutics market, accounting for around 37.6%. For instance, in April 2022, Positive findings from Better Therapeutics' recently finished pivotal study for BT-001, a prescription digital treatment that would be the first of its kind for those with type 2 diabetes, were released.

According to its manufacturer, one of the most prevalent and expensive chronic diseases in the US is to be improved by a new prescription digital treatment. The company claims that over six months, improvements in A1c levels were sustained due to its cognitive-behavioral therapy-focused solution.

Competitive Landscape

The major global players in the market include: Abbott India Ltd, Novo Nordisk, AstraZeneca, Pfizer, Eli Lilly, Dr. Reddy`s Labs, Sanofi, Novartis International, Merck, and Boehringer Ingelheim among others.

Why Purchase the Report?

To visualize the Global Diabetes Therapeutics Market segmentation based on the type, therapy type, end-user, and region and understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of diabetes therapeutics market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as Excel consisting of key products of all the major players.

The Global Diabetes Therapeutics Market Report Would Provide Approximately 61 Tables, 57 Figures And 195 pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

Product Code: PH544

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Type
3.2. Snippet by Therapy Type
3.3. Snippet by End-user
3.4. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Increasing prevalence of diabetes
- 4.1.2. Restraints
  - 4.1.2.1. Side effects associated with diabetes therapeutics
- 4.1.3. Opportunity
  - 4.1.3.1. Technological advancements
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID-19
- 6.1.2. Scenario During COVID-19
- 6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers' Strategic Initiatives
6.6. Conclusion

7. Russia-Ukraine War Analysis

8. Artificial Intelligence Analysis

9. By Type

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 9.1.2. Market Attractiveness Index, By Type
9.2. Type 1 Diabetes*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Type 2 Diabetes
9.4. Gestational Diabetes

10. By Therapy Type

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
- 10.1.2. Market Attractiveness Index, By Therapy Type
10.2. Oral Antidiabetics*
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Injectable Antidiabetics
10.4. Others

11. By End-user

11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
11.1.2. Market Attractiveness Index, By End-user

11.2. Hospitals and Clinics*
- 11.2.1. Introduction
- 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Homecare
11.4. Others

12. By Region

12.1. Introduction
- 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 12.1.2. Market Attractiveness Index, By Region
12.2. North America
- 12.2.1. Introduction
- 12.2.2. Key Region-Specific Dynamics
- 12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
- 12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 12.2.6.1. The U.S.
  - 12.2.6.2. Canada
  - 12.2.6.3. Mexico
12.3. Europe
- 12.3.1. Introduction
- 12.3.2. Key Region-Specific Dynamics
- 12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
- 12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 12.3.6.1. Germany
  - 12.3.6.2. The U.K.
  - 12.3.6.3. France
  - 12.3.6.4. Italy
  - 12.3.6.5. Spain
  - 12.3.6.6. Rest of Europe
12.4. South America
- 12.4.1. Introduction
- 12.4.2. Key Region-Specific Dynamics
- 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
- 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 12.4.6.1. Brazil
  - 12.4.6.2. Argentina
  - 12.4.6.3. Rest of South America
12.5. Asia-Pacific
- 12.5.1. Introduction
- 12.5.2. Key Region-Specific Dynamics
- 12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
- 12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 12.5.6.1. China
  - 12.5.6.2. India
  - 12.5.6.3. Japan
  - 12.5.6.4. Australia
  - 12.5.6.5. Rest of Asia-Pacific
12.6. Middle East and Africa
- 12.6.1. Introduction
- 12.6.2. Key Region-Specific Dynamics
- 12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
- 12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user

13. Competitive Landscape

13.1. Competitive Scenario
13.2. Product Benchmarking
13.3. Company Share Analysis
13.4. Key Developments and Strategies

14. Company Profiles

14.1. Abbott India Ltd*
- 14.1.1. Company Overview
- 14.1.2. Product Portfolio and Description
- 14.1.3. Financial Overview
- 14.1.4. Key Developments
14.2. Novo Nordisk
14.3. AstraZeneca
14.4. Pfizer
14.5. Eli Lilly
14.6. Dr. Reddy`s Labs
14.7. Sanofi
14.8. Novartis International
14.9. Merck
14.10. Boehringer Ingelheim

LIST NOT EXHAUSTIVE

15. Appendix

15.1. About Us and Services
15.2. Contact Us

Global Diabetes Therapeutics Market - 2023-2030